Upcoming Webinar: 18F-FDG PET/CT: Its Role in Clinical Cancer Care

Date: Sept. 13, 2018 Time: 3:00pm EDT

Who should attend? PET Interpreters, Technologists, Referring Physicians, Marketers

Presenter: Johannes Czernin, MD, Director
UCLA Ahmanson Translational Imaging Center

Dr. Johannes Czernin received his MD degree from the University of Vienna in 1983. He was board certified in Internal Medicine in 1989 and in Nuclear Medicine in 1996. He was named Director of Nuclear Medicine at the David Geffen School of Medicine at UCLA in 1996 and currently serves as the Chief of the Ahmanson Translational Imaging Division at UCLA. The Division includes the Nuclear Medicine Clinic, a clinical imaging research program, a drug and probe development program with a strong underpinning in tumor biology, and a new preclinical imaging center. The Division collaborates within the department of molecular and medical pharmacology and across several other departments including medicine, surgery, radiology, neurology, pathology and others. Dr. Czernin is currently Editor-in-Chief of the Journal of Nuclear Medicine and is a past president of the Academy of Molecular Imaging. He serves on the Board of Directors of SOFIE.

He has published more than 160 peer-reviewed research papers.

In this session, Dr. Czernin will:

  • Present an overview of the role of 18F-FDG PET/CT in the management of cancer patient care, focusing on its role as diagnostic, prognostic, intermediate endpoint and predictive biomarker

  • Discuss the diagnostic challenges faced by oncologic physicians and the role of advanced imaging in addressing these questions

  • Focus on areas in which reporting physicians can improve communication with referring physicians

  • Discuss the cost and cost effectiveness of PET/CT imaging

Click here to get the weblink.

Seth Werkheiser